Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | RAD52 | P43351 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30884183 | 1.00 | MAPT (0.53) | MAPTSMN1; SMN2GAAALDH1A1POLB | |
| SCHEMBL14320723 | 0.84 | CYP3A4 (0.46) | MAPTSMN1; SMN2GAAALDH1A1POLB | |
| SCHEMBL17539258 | 0.76 | METAP2 (0.40) | CYP3A4NPC1RAB9A | |
| SCHEMBL29793409 | 0.76 | CASP1 (0.42) | MAPTGAAALDH1A1POLBCYP3A4 | |
| SCHEMBL28524455 | 0.76 | CASP1 (0.42) | MAPTGAAALDH1A1POLBCYP3A4 | |
| SCHEMBL2627309 | 0.76 | ALDH1A1 (0.55) | MAPTSMN1; SMN2GAAALDH1A1POLB | |
| SCHEMBL30884177 | 0.74 | ALDH1A1 (0.46) | MAPTSMN1; SMN2GAAALDH1A1POLB | |
| SCHEMBL15651594 | 0.73 | GAA (0.44) | MAPTSMN1; SMN2GAAALDH1A1POLB | |
| SCHEMBL30517118 | 0.73 | GAA (0.52) | MAPTSMN1; SMN2GAAALDH1A1POLB | |
| SCHEMBL20278384 | 0.73 | MAPT (0.46) | MAPTSMN1; SMN2GAAALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250059196-A1 | TRICYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2025-02-20 | — | — | US | disclosed |
| WO-2025002333-A1 | CRYSTAL FORM OF TRICYCLIC DERIVATIVE INHIBITOR AND PREPARATION METHOD THEREFOR | 上海翰森生物医药科技有限公司 | 2025-01-02 | — | — | WO | disclosed |
| EP-4458819-A1 | TRICYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2024-11-06 | — | — | EP | disclosed |
| EP-3558969-B1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-09-18 | — | — | EP | disclosed |
| US-12077521-B2 | Pyrazole derivatives as MALT1 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2024-09-03 | — | — | US | disclosed |
| US-20240018157-A1 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | SCHRÖDINGER, INC. | 2024-01-18 | — | — | US | disclosed |
| US-20240018157-A1 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | SCHRÖDINGER, INC. | 2024-01-18 | — | — | US | disclosed |
| WO-2023125877-A1 | TRICYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 上海翰森生物医药科技有限公司 | 2023-07-06 | — | — | WO | disclosed |
| WO-2023125877-A1 | TRICYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 上海翰森生物医药科技有限公司 | 2023-07-06 | — | — | WO | disclosed |
| US-20220315557-A1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | JANSSEN BIOTECH, INC. | 2022-10-06 | — | — | US | disclosed |
| US-20180030061-A1 | NOVEL PYRAZOLO PYRIMIDINE DERIVATIVES AND THEIR USE AS MALT1 INHBITORS | NOVARTIS AG (CH) | 2018-02-01 | — | — | US | disclosed |
| US-20180030061-A1 | NOVEL PYRAZOLO PYRIMIDINE DERIVATIVES AND THEIR USE AS MALT1 INHBITORS | NOVARTIS AG (CH) | 2018-02-01 | — | — | US | disclosed |
| US-9815842-B2 | Pyrazolo pyrimidine derivatives and their use as MALT1 inhibitors | NOVARTIS AG (CH) | 2017-11-14 | — | — | US | disclosed |
| US-9815842-B2 | Pyrazolo pyrimidine derivatives and their use as MALT1 inhibitors | NOVARTIS AG (CH) | 2017-11-14 | — | — | US | disclosed |
| US-9815842-B2 | Pyrazolo pyrimidine derivatives and their use as MALT1 inhibitors | NOVARTIS AG (CH) | 2017-11-14 | — | — | US | disclosed |
| US-20170121335-A1 | NOVEL PYRAZOLO PYRIMIDINE DERIVATIVES AND THEIR USE AS MALT1 INHBITORS | NOVARTIS AG (CH) | 2017-05-04 | — | — | US | disclosed |
| US-20170121335-A1 | NOVEL PYRAZOLO PYRIMIDINE DERIVATIVES AND THEIR USE AS MALT1 INHBITORS | NOVARTIS AG (CH) | 2017-05-04 | — | — | US | disclosed |
| US-20170121335-A1 | NOVEL PYRAZOLO PYRIMIDINE DERIVATIVES AND THEIR USE AS MALT1 INHBITORS | NOVARTIS AG (CH) | 2017-05-04 | — | — | US | disclosed |
| EP-3149001-A1 | NOVEL PYRAZOLO PYRIMIDINE DERIVATIVES AND THEIR USE AS MALT1 INHIBITORS | Novartis AG (CH) | 2017-04-05 | — | — | EP | disclosed |
| WO-2015181747-A1 | NOVEL PYRAZOLO PYRIMIDINE DERIVATIVES AND THEIR USE AS MALT1 INHIBITORS | NOVARTIS AG (CH) | 2015-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180030061-A1 | NOVEL PYRAZOLO PYRIMIDINE DERIVATIVES AND THEIR USE AS MALT1 INHBITORS | MMEL1, MALT1, FBP1 | MAPT 3131/4885SMN1; SMN2 3729/4885GAA 236/4885 |
| US-20220315557-A1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | MALT1, PPP3R1, SQSTM1 | MAPT 2314/4885SMN1; SMN2 2224/4885GAA 254/4885 |
| US-20250059196-A1 | TRICYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | WEE1, CYP51A1, WEE2 | MAPT 4276/4885SMN1; SMN2 4850/4885GAA 2080/4885 |
| US-20170121335-A1 | NOVEL PYRAZOLO PYRIMIDINE DERIVATIVES AND THEIR USE AS MALT1 INHBITORS | MMEL1, MALT1, FBP1 | MAPT 3131/4885SMN1; SMN2 3729/4885GAA 236/4885 |
| US-12077521-B2 | Pyrazole derivatives as MALT1 inhibitors | MALT1, PPP3R1, SQSTM1 | MAPT 2314/4885SMN1; SMN2 2224/4885GAA 254/4885 |
| US-20240018157-A1 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | MALT1, FKBP1B, FKBP1A | MAPT 3951/4885SMN1; SMN2 2382/4885GAA 320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.